Immunotherapy in GU Cancers Articles | Page 2

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1
Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC
The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.
Immunotherapy Combinations on the Rise for RCC
The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.
Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer
Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.
Future of Bladder Cancer Care to Include Immunotherapy Combos
Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.
Immunotherapy Continues to Shape Future Bladder Cancer Paradigm
Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.
Next Steps in Bladder Cancer to Include Combination Immunotherapy
Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.
Pembrolizumab, Atezolizumab New Standards for Bladder Cancer
A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.
NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
Publication Bottom Border
Border Publication